SAB Biotherapeutics, Inc.
SABS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | -0.15 | 0.11 |
| FCF Yield | -98.65% | -66.65% | -27.99% | -2.12% |
| EV / EBITDA | -1.06 | 0.33 | -1.09 | -20.72 |
| Quality | ||||
| ROIC | -115.89% | -50.78% | -77.62% | -22.49% |
| Gross Margin | -262.48% | -67.26% | 86.23% | 97.28% |
| Cash Conversion Ratio | 1.01 | 0.60 | 1.25 | -0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -61.90% | -66.74% | -24.36% | 160.54% |
| Free Cash Flow Growth | -36.79% | -252.35% | 0.00% | -163.49% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 1.33 | 0.60 | 1.62 |
| Interest Coverage | -134.77 | -120.76 | -95.89 | -45.48 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -113.88 | -92.19 | -323.08 | -935.86 |